“Construction of CDMO plant with 100,000-liter domestic capacity planned; construction set for H2 2025”
[by Kang, In Hyo] “We are contemplating mergers and acquisitions (M&A) of prominent Korean health functional food companies, such as those specializing in ginseng and red ginseng, through 슬롯사이트 볼트 Holdings, the 슬롯사이트 볼트 Group’s holding company, as part of our preparations for a listing on the U.S. Nasdaq market.”
Celltrion founder and Chairman 슬롯사이트 볼트 Jung-jin made this announcement during a press conference at the ‘2025 J.P. Morgan Healthcare Conference,’ the world’s largest pharmaceutical and biotechnology investment event that opened in San Francisco, USA, on January 14 (local time). At the event, 슬롯사이트 볼트 reiterated plans to pursue a Nasdaq listing for Celltrion Holdings.
“Last year, we unveiled our intention to seek a Nasdaq listing for Celltrion Holdings, however, we postponed the plan as it would have incurred financial losses at the time,” 슬롯사이트 볼트 stated.
Since Celltrion Holdings operates solely as a holding company without an independent business division, 슬롯사이트 볼트 intends to reduce his personal stake (currently 98.5%) by acquiring operational companies that generate revenue and profits. This strategy will help meet the necessary requirements for a Nasdaq listing.
“We plan to carry out large-scale M&A activities in the fourth quarter of this year,” 슬롯사이트 볼트 expressed. “Celltrion Holdings will acquire leading ‘K-food’ health supplement companies, promote them around the world, and, through this M&A strategy, aim to pursue a Nasdaq listing again by around 2027.”
“At present, Korean companies’ stock prices are significantly undervalued, but I anticipate they will recover from this low point around the third quarter,” 슬롯사이트 볼트 further emphasized. “During that time, we plan to acquire promising domestic companies that are facing financial difficulties, ensuring that valuable companies do not collapse.”
Chairman 슬롯사이트 볼트 Jung-jin also commented on Celltrion BioSolutions, a contract development and manufacturing organization (CDMO) established late last year, saying, “We are focusing on our strengths,” and added, “We plan to expand our capacity by 100,000 to 150,000 liters in the future.”
“We intend to finalize a detailed expansion plan by the first half of this year, with plans to build a 100,000-liter facility in Korea,” 슬롯사이트 볼트 further commented. “We are securing locations in Songdo, Incheon, South Chungcheong Province, and North Chungcheong Province, and construction will begin in the second half of the year once a domestic plant site is chosen.”
슬롯사이트 볼트 also outlined plans to develop an obesity treatment drug. “We are in the process of planning animal testing on candidates for oral glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP) dual agonists, as well as a triple agonist with one undisclosed target,” he explained. “We expect to begin animal testing on the oral GLP-1 triple agonist candidate in 2 to 3 years, after selecting the target.”
Lastly, 슬롯사이트 볼트 reflected on building a global direct sales network, saying, “I traveled extensively to every corner of many countries to establish our own sales network around the world, putting in the effort to secure it as a salesperson, despite being the chairman.” He added, “Building this sales network was more challenging than developing the drug itself.” He continued, “When you put in the work, like a peddler going from market to market, opportunities eventually open up. Our direct sales network is a key competitive advantage we have established on a global scale.”